Future studies should aim to elucidate the signaling pathways through which MTA3 modulates placental development and evaluate the translational potential of targeting the MTA family or implementing progesterone-based interventions for IUGR prevention and management. The gene discussed is MTA3; the disease is fetal growth restriction.